Human to pet in just one step.

Our proprietary PETization platform enables the rapid translation of therapeutic monoclonal antibodies (mAbs) between species.

Our mAbs are uniquely designed to be accepted by a patient's immune system as "native," a property we refer to as "100% species-specificity."

Our most advanced therapies in development are focused on treatments within four general areas: chronic pain, chronic inflammation, allergy, and immuno-oncology (cancer).

We believe biologic therapies as a class offer significant advantages over current treatments in these areas, including: safety, longer duration of action (and therefore less frequent dosing), and injectability.

Our team of scientists and veterinarians are working to investigate further opportunities for new biologic therapies.

A diverse team of experts who are passionate about animal health.

Meet our team

Nexvet on tour

12-14 June 2017

VetHealth Global, Prince Edward Island, Canada.

Keep up with the transformation

Hear more — follow us on social media, browse extra content, and subscribe to our newsletter here.

Introducing ranevetmab: designed for dogs


19 March 2017

This article in @nytimes explains dog cognition research and how it’s changing the way “owners view their animals.”

Register for Our Newsletter

Nexvet Biopharma

Unit 5, Sragh Technology Park
Rahan Road, Tullamore
Co. Offaly, R35 FR98
P: + 353 5793 24522 

Level 8, 31 Queen Street
Melbourne 3000
P: +61 (3) 9610 4400

United States
275 Post Street
4th Floor
San Francisco, CA 94108


Get in Touch